Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2303]

One-year mortality in older adults with breast cancer: prediction using...

Dr Tabassum Wadasadawala and Dr Shivani Sable

One-year mortality in older adults with breast cancer: prediction using different geriatric tools ( Dr Tabassum Wadasadawala and Dr Shivani Sable )

Isa-VRd shows greater efficacy compared to VRd in transplant-ineligible NDMM...

Prof Meletios Dimopoulos - University of Athens, Athens, Greece

Isa-VRd shows greater efficacy compared to VRd in transplant-ineligible NDMM patients ( Prof Meletios Dimopoulos - University of Athens, Athens, Greece )

Optimising benefit-risk and minimising impact on quality of life with BCMA...

Prof Meletios Dimopoulos - University of Athens, Athens, Greece

Optimising benefit-risk and minimising impact on quality of life with BCMA-targeting agents in an outpatient setting ( Prof Meletios Dimopoulos - University of Athens, Athens, Greece )

Understanding the remaining unmet needs in a post ASCT NDMM setting

Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway

Understanding the remaining unmet needs in a post ASCT NDMM setting ( Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway )

Approaches to risk stratification in high risk myeloma

Dr Irene Ghobrial - Dana-Farber Cancer Institute, Boston, USA

Approaches to risk stratification in high risk myeloma ( Dr Irene Ghobrial - Dana-Farber Cancer Institute, Boston, USA )

Use of bispecifics and CAR T cells in South America

Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA

Use of bispecifics and CAR T cells in South America ( Dr Jesus Berdeja - Sarah Cannon Research Institute, Nashville, USA )

Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance...

Dr Jill Corre - IUCT Oncopole, Toulouse, France

Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM ( Dr Jill Corre - IUCT Oncopole, Toulouse, France )

Revolutionising myeloma treatment through immune profiling

Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA

Revolutionising myeloma treatment through immune profiling ( Dr Romanos Sklavenitis-Pistofidis - Dana-Farber Cancer Institute, Boston, USA )

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies

Prof Joy Ho - The University of Sydney, Sydney, Australia

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies ( Prof Joy Ho - The University of Sydney, Sydney, Australia )

Contribution of constitutional BRCA1 promoter methylation to early-onset and...

Dr Muhammad Usman Rashid - Shaukat Khanum Memorial Cancer Hospital & Research...

Contribution of constitutional BRCA1 promoter methylation to early-onset and familial breast cancer patients from Pakistan ( Dr Muhammad Usman Rashid - Shaukat Khanum Memorial Cancer Hospital & Research Centre, Lahore, Pakistan )

ESMO and WCLC: Latest developments in EGFR mutated NSCLC

Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale...

ESMO and WCLC: Latest developments in EGFR mutated NSCLC ( Dr Matthew Krebs, Dr Antonio Passaro, Dr Enriqueta Felip and Prof Pascale Tomasini )

Cabozantinib demonstrates significant improvement in PFS by BICR in advanced...

Dr Jennifer Chan - Dana-Farber Cancer Institute, Boston, USA

Cabozantinib demonstrates significant improvement in PFS by BICR in advanced neuroendocrine tumours ( Dr Jennifer Chan - Dana-Farber Cancer Institute, Boston, USA )

More from ecancer